AceLink Therapeutics Receives Orphan Drug Designation for its Novel GCS Inhibitor AL01211 for the…
AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, announced it has received Orphan Drug Designation…
Read More...
Read More...